KEY DETAILS
The MHRA announced on October 15, 2026 that counterfeit weight loss medicines worth about £2 million were seized the night before in a raid with West Midlands Police.
A cohort study dated October 14, 2026 reported that tirzepatide treatment initiation and switching changed markedly around a price increase among self-paying UK adults with overweight or obesity.
A hypothesis-generating cohort study dated October 14, 2026 found GLP-1 receptor agonist use associated with lower risk of lower extremity amputation in adults with type 2 diabetes and foot ulcer.
A Phase 2 feasibility trial dated October 15, 2026, not yet recruiting, plans to study tirzepatide in young adult sarcoma survivors who are overweight or obese.
Two trials dated October 15, 2026, both not yet recruiting, plan to study semaglutide's effects on body composition and performance in well-trained runners, one long-term and one short-term.
They range from a counterfeit seizure in the UK to new research on how tirzepatide and GLP-1 medicines are used and studied. None of what follows is medical advice.
The MHRA and West Midlands Police carried out a raid that seized counterfeit weight loss medicines worth approximately £2 million. In a press release published October 15, 2026, the MHRA said the seizure took place the night before. The MHRA listed this as enforcement and a public warning.
A cohort study dated October 14, 2026 in Diabetes, Obesity and Metabolism covered over one million self-paying UK adults with overweight or obesity who used a single UK telehealth provider. The study looked at treatment patterns and weight outcomes before and after a tirzepatide price increase. It reported that treatment initiation and switching changed markedly around the increase.
A cohort study dated October 14, 2026 in Diabetes, Obesity and Metabolism found that GLP-1 receptor agonist use was associated with lower risk of lower extremity amputation in adults with type 2 diabetes and foot ulcer who had no coded peripheral arterial disease. The association held up across six pre-specified sensitivity analyses. The authors describe these observational findings as hypothesis-generating and say they require prospective confirmation.
The PROACT AYA trial, dated October 15, 2026 on ClinicalTrials.gov, is a single-arm, single-center, open-label Phase 2 feasibility study of tirzepatide sponsored by M.D. Anderson Cancer Center. It plans to enroll 30 young adults, ages 18 to 39, with soft tissue or bone sarcoma who are overweight or obese, completed doxorubicin-based chemotherapy about three months before enrollment, and have preserved heart function. The trial is not yet recruiting; its listed start date is December 31, 2026 and its listed completion date is December 31, 2036.
Two trials dated October 15, 2026 are sponsored by Morten Hostrup, PhD. Each is a randomized, placebo-controlled parallel study of semaglutide in well-trained male and female runners, one looking at long-term effects and the other at short-term effects. They aim to measure body composition, muscle mass, volume and function, running economy, and performance, with the long-term study also measuring hormonal markers, and each plans 41 participants. Both are not yet recruiting, with listed start dates of October 14, 2026 and completion dates of April 30, 2028.
These are the six developments dated October 14 and 15, 2026. The seizure was announced by the MHRA, the two cohort studies were published in Diabetes, Obesity and Metabolism, and the three trials are registered on ClinicalTrials.gov, where you can read each one in full.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.